Improved Survival with Integration of Chinese Herbal Medicine Therapy in Patients with Acute Myeloid Leukemia: A Nationwide Population-Based Cohort Study

Integrative Cancer Therapies

Volumn 16, Issue 2, 2017, Pages 156-164

  Fleischer, Tom ^a   Chang, Tung Ti ^a,b   Chiang, Jen Huai ^b   Sun, Mao Feng ^a,b   Yen, Hung Rong ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

acute myeloid leukemia; Chinese medicine; leukemia; NHIRD; Taiwan

Indexed keywords

GUI PI TANG; HERBACEOUS AGENT; JIA WEI XIAO YAO SAN; QI JU DU HUANG WAN; UNCLASSIFIED DRUG; DAN-SHEN ROOT EXTRACT; HUANG QI;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ARTICLE; ASTRAGALUS MEMBRANACEUS; CANCER SURVIVAL; CHINESE HERB; CHINESE MEDICINE; COHORT ANALYSIS; COMORBIDITY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; POPULATION RESEARCH; PRIORITY JOURNAL; SALVIA MILTIORRHIZA; SPATHOLOBUS SUBERECTUS; ADOLESCENT; ALTERNATIVE MEDICINE; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMPLEMENTARY THERAPIES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 85019626438     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735416664171     Document Type: Article

References (36)

1. Dohner H, Lubbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014; 124: 1426-1433.
2. Comparative Study on Spleen with TCM and Western Medicine. Zhejiang J Tradit Chin Med. 2006; 41: 1-6.
3. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF,. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973; 57: 485-488.
4. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60: 454-462.
5. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58: 1203-1212.
6. Tefferi A, Letendre L,. Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol. 2012; 30: 2425-2428.
7. Lowenberg B, Downing JR, Burnett A,. Acute myeloid leukemia. N Engl J Med. 1999; 341: 1051-1062.
8. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332: 217-223.
9. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009; 27: 5397-5403.
10. American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015.
11. Lin SJ, Cheng YY, Chang CH, Lee CH, Huang YC, Su YC,. Traditional Chinese medicine diagnosis "yang-xu zheng": significant prognostic predictor for patients with severe sepsis and septic shock. Evid Based Complement Alternat Med. 2013; 2013: 759748.
12. Hui H, Chen Y, Yang H, et al. Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARgamma and RXRalpha. Int J Cancer. 2014; 134: 1195-1206.
13. Li X, Yang G, Li X, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PLoS One. 2013; 8: e60338.
14. Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res. 2007; 7: 26.
15. Office of Information Services, Executive Yuan. The Republc of China (Taiwan): ROC Yearbook 2013. http://http://www.ey.gov.tw/en/ [. Accessed August 2016)]
16. Huang TP, Liu PH, Lien AS, Yang SL, Chang HH, Yen HR,. A nationwide population-based study of traditional Chinese medicine usage in children in Taiwan. Complement Ther Med. 2014; 22: 500-510.
17. Fleischer T, Chang TT, Chiang JH, Chang CM, Hsieh CY, Yen HR,. Adjunctive Chinese herbal medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population-based cohort study. Cancer Med. 2016; 5: 640-648.
18. Lee AL, Chen BC, Mou CH, Sun MF, Yen HR,. Association of traditional Chinese medicine therapy and the risk of vascular complications in patients with type ii diabetes mellitus: a nationwide, retrospective, Taiwanese-registry, cohort study. Medicine (Baltimore). 2016; 95: e2536.
19. Huang MC, Pai FT, Lin CC, et al. Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2015; 176: 9-16.
20. Huang TP, Liu PH, Lien AS, Yang SL, Chang HH, Yen HR,. Characteristics of traditional Chinese medicine use in children with asthma: a nationwide population-based study. Allergy. 2013; 68: 1610-1613.
21. Huang CY, Lai WY, Sun MF, et al. Prescription patterns of traditional Chinese medicine for peptic ulcer disease in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2015; 176: 311-320.
22. Breccia M, Frustaci AM, Cannella L, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009; 27: 148-153.
23. Guo H, Liu L, Baak JP,. Is the improvement of prognosis of patients with metastatic pulmonary adenocarcinoma treated with TCM herbal medicine due to lag time to treatment bias? Integr Cancer Ther. 2011; 10: 234-239.
24. Boon HS, Olatunde F, Zick SM,. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health. 2007; 7: 4.
25. Fasching PA, Thiel F, Nicolaisen-Murmann K, et al. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer. 2007; 15: 1277-1284.
26. Kremser T, Evans A, Moore A, et al. Use of complementary therapies by Australian women with breast cancer. Breast. 2008; 17: 387-394.
27. Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013; 121: 2618-2626.
28. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009; 113: 28-36.
29. Cheng C-L, Li C-C, Hou H-A, et al. Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer. 2015; 15: 344.
30. Levis M, Small D,. FLT3: ITDoes matter in leukemia. Leukemia. 2003; 17: 1738-1752.
31. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T,. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005; 19: 1345-1349.
32. Zhang W, Konopleva M, Shi Y-X, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008; 100: 184-198.
33. Deschler B, Lubbert M,. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006; 107: 2099-2107.
34. Juliusson G, Antunovic P, Derolf Å et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009; 113: 4179-4187.
35. Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C,. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica. 2005; 90: 1502-1510.
36. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT,. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica. 2003; 88: 416-428.